Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Daniel Todt
  • ,
  • Catherine François
  • ,
  • [Ukendt] Anggakusuma
  • ,
  • Patrick Behrendt
  • ,
  • Michael Engelmann
  • ,
  • Leonard Knegendorf
  • ,
  • Gabrielle Vieyres
  • ,
  • Heiner Wedemeyer
  • ,
  • Rune Hartmann
  • Thomas Pietschmann
  • ,
  • Gilles Duverlie
  • ,
  • Eike Steinmann

Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genusOrthohepevirusin the familyHepeviridae HEV infections are the common cause of acute hepatitis but can also take chronic courses. Ribavirin is the treatment of choice for most patients, and type I interferon (IFN) has been evaluated in a few infected transplant patientsin vivo In this study, the antiviral effects of different exogenously administered interferons were investigated by using state-of-the-art subgenomic replicon and full-length HEV genome cell culture models. Hepatitis C virus (HCV) subgenomic replicons based on the genotype 2a JFH1 isolate served as the reference. The experiments revealed that HEV RNA replication was inhibited by the application of all types of IFN, including IFN-α (type I), IFN-γ (type II), and IFN-λ3 (type III), but to a far lesser extent than HCV replication. Simultaneous determination of interferon-stimulated gene (ISG) expression levels for all IFN types demonstrated efficient downregulation by HEV. Furthermore, different IFN-α subtypes were also able to block viral replication in combination with ribavirin. The IFN-α subtypes 2a and 2b exerted the strongest antiviral activity against HEV. In conclusion, these data demonstrate for the first time moderate anti-HEV activities of types II and III IFNs and different IFN-α subtypes. As HEV employed a potent anti-interferon mechanism by restricting ISG expression, exogenous application of IFNs as immunotherapy should be carefully assessed.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue4
Pages (from-to)2132-2139
Number of pages8
ISSN0066-4804
DOIs
Publication statusPublished - Jan 2016

See relations at Aarhus University Citationformats

ID: 99584707